Fruchart, Jean-Charles

Increased ABCA1 activity protects against atherosclerosis

Singaraja, R. R., Fievet, C., Castro, G., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J.-C., McManus, B. M., et al. (2002) · Journal of Clinical Investigation

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 250

PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance

Guerre-Millo, M., Rouault, C., Poulain, P., André, J., Poitout, V., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Reach, G., & Staels, B. (2001) · Diabetes

Peroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 241

Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes.

Dehouck, B., Dehouck, M. P., Fruchart, J. C., & Cecchelli, R. (1994) · The Journal of cell biology

Barrier Structure and Function StudiesCholesterol and Lipid Metabolism

Cited by 240

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

Fruchart, J.-C. (2009) · Atherosclerosis

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 233

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 208

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Fruchart, J.-C. (2013) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 189

Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription

Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B. (2002) · Journal of Lipid Research

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 183

Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation

Lipid metabolism and disordersRetinoids in leukemia and cellular processes

Cited by 143

Low‐Density Lipoprotein Receptor on Endothelium of Brain Capillaries

Méresse, S., Delbart, C., Fruchart, J., & Cecchelli, R. (1989) · Journal of Neurochemistry

Barrier Structure and Function StudiesCholesterol and Lipid Metabolism

Cited by 143

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Fruchart, J.-C. (2017) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 141

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde

Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 114

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

Brunham, L. R., Singaraja, R. R., Duong, M., Timmins, J. M., Fievet, C., Bissada, N., Kang, M. H., Samra, A., Fruchart, J.-C., McManus, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 102

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists

Yamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters

Peroxisome Proliferator-Activated ReceptorsHeterocyclic Compound Synthesis and Bioactivity

Cited by 84

4-Mercaptoimidazoles Derived From the Naturally Occurring Antioxidant Ovothiols 1. Antioxidant Properties

Zoete, V., Bailly, F., Vezin, H., Teissier, E., Duriez, P., Fruchart, J.-C., Catteau, J.-P., & Bernier, J.-L. (2000) · Free Radical Research

Free Radicals and AntioxidantsAntioxidant Activity and Oxidative Stress

Cited by 27

Influence of mental stress and circadian cycle on postprandial lipemia

Le Fur, C., Romon, M., Lebel, P., Devos, P., Lancry, A., Guédon-Moreau, L., Fruchart, J.-C., & Dallongeville, J. (1999) · The American Journal of Clinical Nutrition

Lipid metabolism and disordersLipid metabolism and biosynthesis

Cited by 27

Lessons from PROMINENT and prospects for pemafibrate

Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLiver Disease Diagnosis and Treatment

Cited by 16